Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

Inclusion Criteria: 1. Age 18-75 years old, no gender limit; 2. Histologically diagnosed as diffuse large B-cell lymphoma (DLBCL), transforming follicular lymphoma (TFL), primary mediastinal B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL) and other inert B-cells NHL conversion type: 1. Refractory or relapsed DLBCL refers to the failure to achieve complete remission after 2-line treatment; disease progression during any treatment, or disease stable time equal to or less than 6 months; or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation ； 2. Refractory or relapsed MCL must be resistant to or intolerable to BTK inhibitors; 3. Refractory or relapsed indolent B-cell NHL is the failure or recurrence of third-line treatment; 3. Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative) and anthracyclines; 4. At least one measurable lesion with the longest diameter ≥ 1.5 cm exists; 5. The expected survival period is ≥12 weeks; 6. The puncture section of the tumor tissue was positive for CD19 expression; 7. ECOG score 0-2 points; 8. Sufficient organ function reserve: 1. Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL (upper limit of normal value); 2. Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min; 3. Serum total bilirubin and alkaline phosphatase ≤1.5× UNL; 4. Glomerular filtration rate\>50Ml/min 5. Cardiac ejection fraction (EF) ≥50%; 6. Under natural indoor air environment, basic oxygen saturation\>92% 9. Allow a previous stem cell transplantation 10. The approved anti-B-cell lymphoma treatments, such as systemic chemotherapy, systemic radiotherapy, and immunotherapy, have been completed for at least 3 weeks before the study medication; 11. Allow patients who have previously received CAR-T cell therapy and have failed or relapsed after 3 months of evaluation; 12. Female subjects of childbearing age must have a negative pregnancy test and agree to take effective contraceptive measures during the trial 13. Two tests for the new coronavirus or swine flu virus are negative. Exclusion Criteria: 1. Allergic to any of the components of cell products; 2. History of other tumors; 3. Acute GvHD or extensive chronic GvHD with grade II-IV (Glucksberg standard) in the past or are receiving anti-GVHD treatment; 4. Had received gene therapy within the past 3 months; 5. Active infections requiring treatment (except for simple urinary tract infections, bacterial pharyngitis); however, prophylactic antibiotics, antiviral and antifungal infection treatment are permitted; 6. Patents infected with hepatitis B (HBsAg positive, but HBV-DNA \< 103 is not excluded) or hepatitis C virus (including virus carriers), syphilis and other acquired and congenital immunodeficiency diseases, including but not limited to HIV-infected persons; 7. Subjects with Grade III or IV cardiac dysfunction according to the New York Heart Association\'s cardiac function grading criteria; 8. Patients who received antitumor therapy earlier but did not recover from the toxicity (CTCAE 5.0 toxicity did not recover to ≤ grade 1, except fatigue, anorexia, alopecia); 9. Subjects with a history of epilepsy or other central nervous system disorders; 10. Head-enhanced CT or MRI showing evidence of central nervous system lymphoma; 11. Lactating women who are unwilling to stop breastfeeding; 12. Any other factors that the investigator believes may increase the risk to the subject or interfere with the test results.